SOL Strategies Inc. reported that Houdini Swap, its privacy-focused cross-chain swap platform, saw trading volume increase to approximately US$74 million in August 2026, up 14% from June. Over the three months ending August, Houdini executed over 120,000 orders totaling about US$206 million, with 55% involving the Solana blockchain and 74% of August volume through private swaps. This growth reflects rising cryptocurrency prices and new partnerships, supporting SOL Strategies' focus on privacy and user control in blockchain transactions. The company also announced participation in the Water Tower Research Insights Conference and a leadership role change for Stephen Ehrlich.
SOL Strategies' Houdini Swap monthly volume increase is the subject, with a 14% rise reported over June. For readers following US stocks on Pluang, 47 of 150 priced stocks rose while 98 fell, including Li Auto Inc at USD 11.88 (-2.38%), Robinhood Markets at USD 111.76 (-2.25%), and Firy Inc. at USD 10.10 (-1.94%). This data is as of Sep 15, 2026 19:11 WIB.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
